Christopher A Campbell

20100144653, Jun 10, 2010

May 24, 2006

11/920909

Kevin J. Yarema - Woodstock MD, US
Mark B. Jones - Baltimore NY, US
Christopher T. Campbell - Baltimore MD, US
Udayanath Aich - Baltimore MD, US

The Johns Hopkins University - Baltimore MD

A61K 31/7028
C07H 15/12
A61P 35/00
A61P 1/00
A61P 19/02
A61P 9/10
A61P 37/06
A61P 25/16
A61P 25/14
A61P 1/04

514 25, 536 172

Described herein are fatty acid carbohydrate hybrid compounds and derivatives thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions thereof.

20110206734, Aug 25, 2011

Aug 7, 2008

12/671994

Kevin J. Yarema - Woodstock MD, US
Udayanath Aich - Baltimore MD, US
Christopher Thomas Campbell - Baltimore MD, US
Srinivasa-Gopalan Sampathkumar - New Delhi, IN
Sean S. Choi - Baltimore MD, US
Michael Adam Meledeo - Odenton MD, US
Christopher Weier - Baltimore MD, US

THE JOHNS HOPKINS UNIVERSITY - Baltimore MD

A61K 39/00
C07H 15/04
A61K 31/7028
C07H 13/04
A61K 31/7024
A61P 35/00
C12N 5/071

4242771, 536 182, 514 25, 536 53, 514 62, 435375

Described herein are fatty acid carbohydrate-hydroxyl-hybrid compounds and derivatives thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions thereof.

20230021837, Jan 26, 2023

Nov 25, 2020

17/779900

- Rockville MD, US
Mingyue WANG - Potomac MD, US
Christopher CAMPBELL - Columbia MD, US
Katarzyna HAYNESWORTH - Buckeystown MD, US
Nikhil PADMANABHAN - McLean VA, US
Martin STENGELIN - Gaithersburg MD, US
Paridhi GUPTA - Boyds MD, US
Rashmi SRIRAM - Gaithersburg MD, US

G01N 33/564
G01N 33/543

The invention relates to assay methods and kits for assessing autoimmune diseases in a human subject. In embodiments, the present disclosure provides assay methods and kits for diagnosing a subject with or predicting that a subject will develop Type 1 diabetes. In embodiments, the present disclosure provides assay methods and kits for assessing responsiveness of a subject having Type 1 diabetes to treatment with alefacept. In embodiments, the present disclosure provides assay methods and kits for diagnosing a subject with systemic lupus erythematosus. In embodiments, the present disclosure provides assay methods and kits for determining if a subject is at risk of a systemic lupus erythematosus flare. In embodiments, the present disclosure provides assay methods and kits for diagnosing a subject with celiac disease.

20170052185, Feb 23, 2017

Nov 8, 2016

15/345634

- Bethesda MD, US
Christopher Campbell - Baltimore MD, US
Oyindasola Oyelaran - Boston MA, US
James Gulley - Takoma Park MD, US
Jeffrey Schlom - Potomac MD, US

The United States of America, as represented by the Secretary, Department of Health and Human Serv - Bethesda MD

G01N 33/574
A61K 39/00

The invention provides a method for predicting the clinical response to a cancer vaccine in a patient having cancer, a method for determining the immune response to a cancer vaccine in a patient having cancer who has been administered a cancer vaccine, a method for determining the long-term survival in a patient having cancer, corresponding kits therefor, as well as methods of for improving the efficacy of a virus-based vaccine.